Review



hpv16 2a3 cell line  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    ATCC hpv16 2a3 cell line
    Lactate dehydrogenase assay of CasKi and <t>2A3</t> cells treated in vitro with various concentrations of cisplatin.
    Hpv16 2a3 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 39 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hpv16+2a3+cell+line/2A3/pmc03590678-10-1-16
    Average 94 stars, based on 39 article reviews
    hpv16 2a3 cell line - by Bioz Stars, 2026-10
    94/100 stars

    Images

    1) Product Images from "Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein"

    Article Title: Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein

    Journal: British Journal of Cancer

    doi: 10.1038/bjc.2013.43

    Lactate dehydrogenase assay of CasKi and 2A3 cells treated in vitro with various concentrations of cisplatin.
    Figure Legend Snippet: Lactate dehydrogenase assay of CasKi and 2A3 cells treated in vitro with various concentrations of cisplatin.

    Techniques Used: Lactate Dehydrogenase Assay, In Vitro

    Tumour uptake of E6-binding mAb 188 Re-C1P5 in nude mice-bearing CasKi and 2A3 tumours post treatment with cisplatin. Mice were treated with various doses of cisplatin for 3 days, 188 Re-C1P5 mAb was administered 24 h after the last dose of cisplatin, and the tumour uptake was assessed 24 h post 188 Re-C1P5 administration: ( A ) CasKi; ( B ) 2A3; ( C , D ) TUNEL staining of the untreated and cisplatin-treated tumours. Apoptotic cells stained brown. Original magnification × 400: ( C ) CasKi tumours—untreated (left panel) and treated with 5 mg kg −1 cisplatin (right panel); ( D ) 2A3 tumours—untreated (left panel) and treated with 5 mg kg −1 cisplatin (right panel).
    Figure Legend Snippet: Tumour uptake of E6-binding mAb 188 Re-C1P5 in nude mice-bearing CasKi and 2A3 tumours post treatment with cisplatin. Mice were treated with various doses of cisplatin for 3 days, 188 Re-C1P5 mAb was administered 24 h after the last dose of cisplatin, and the tumour uptake was assessed 24 h post 188 Re-C1P5 administration: ( A ) CasKi; ( B ) 2A3; ( C , D ) TUNEL staining of the untreated and cisplatin-treated tumours. Apoptotic cells stained brown. Original magnification × 400: ( C ) CasKi tumours—untreated (left panel) and treated with 5 mg kg −1 cisplatin (right panel); ( D ) 2A3 tumours—untreated (left panel) and treated with 5 mg kg −1 cisplatin (right panel).

    Techniques Used: Binding Assay, TUNEL Assay, Staining

    Therapy with cisplatin and RIT with E6-binding mAb 188 Re-C1P5 of nude mice-bearing 2A3 ( A ) and CasKi ( B ) tumours. T n—tumour volume on the day of measurement; T 0 —tumour volume on day 0. The mice with 2A3 HNSCC tumours were treated IP with: 400 μ Ci 188 Re-C1P5 mAb on day 0; or 5 mg kg −1 per day cisplatin on days 0, 1, 2 followed by 400 μ Ci 188 Re-C1P5 mAb on day 3; or 5 mg kg −1 cisplatin alone on days 0, 1, 2; or left untreated. The mice with CasKi cervical tumours were treated IP with: 200 μ Ci 188 Re-C1P5 mAb on day 0; or 5 mg kg −1 per day cisplatin on days 0, 1, 2 followed by 200 μ Ci 188 Re-C1P5 mAb on day 3; or 5 mg kg −1 cisplatin alone on days 0. 1, 2; or left untreated.
    Figure Legend Snippet: Therapy with cisplatin and RIT with E6-binding mAb 188 Re-C1P5 of nude mice-bearing 2A3 ( A ) and CasKi ( B ) tumours. T n—tumour volume on the day of measurement; T 0 —tumour volume on day 0. The mice with 2A3 HNSCC tumours were treated IP with: 400 μ Ci 188 Re-C1P5 mAb on day 0; or 5 mg kg −1 per day cisplatin on days 0, 1, 2 followed by 400 μ Ci 188 Re-C1P5 mAb on day 3; or 5 mg kg −1 cisplatin alone on days 0, 1, 2; or left untreated. The mice with CasKi cervical tumours were treated IP with: 200 μ Ci 188 Re-C1P5 mAb on day 0; or 5 mg kg −1 per day cisplatin on days 0, 1, 2 followed by 200 μ Ci 188 Re-C1P5 mAb on day 3; or 5 mg kg −1 cisplatin alone on days 0. 1, 2; or left untreated.

    Techniques Used: Binding Assay

    18 F-FDG microPET/CT images of 2A3 tumour-bearing on day 15 post treatment: left panel—untreated mouse, middle panel—the mouse treated with cisplatin alone, right panel—the mouse treated with cisplatin and RIT. Green arrows are pointing to the tumours.
    Figure Legend Snippet: 18 F-FDG microPET/CT images of 2A3 tumour-bearing on day 15 post treatment: left panel—untreated mouse, middle panel—the mouse treated with cisplatin alone, right panel—the mouse treated with cisplatin and RIT. Green arrows are pointing to the tumours.

    Techniques Used:

    Immunohistochemical evaluation of E6 and E7 oncogenes expression in RIT-treated CasKi and 2A3 cells. ( A ) E6 in CasKi cells, ( B ) E7 in CasKi cells; ( C ) E6 in 2A3 cells; ( D ) E7 in 2A3 cells. Left panels show untreated cells and right panels RIT-treated cells. Cells positive for E6 and E7 oncogenes stained brown. Original magnification × 400.
    Figure Legend Snippet: Immunohistochemical evaluation of E6 and E7 oncogenes expression in RIT-treated CasKi and 2A3 cells. ( A ) E6 in CasKi cells, ( B ) E7 in CasKi cells; ( C ) E6 in 2A3 cells; ( D ) E7 in 2A3 cells. Left panels show untreated cells and right panels RIT-treated cells. Cells positive for E6 and E7 oncogenes stained brown. Original magnification × 400.

    Techniques Used: Immunohistochemical staining, Expressing, Staining

    Related Articles

    Produced:

    Article Title: Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein
    Article Snippet: The HPV16+ CasKi cell line was obtained from the American Type Culture Collection (Manassas, VA, USA). .. The HPV16+ 2A3 cell line was produced by stably transfecting the FaDu cell line from the American Type Culture Collection with the LXSN 16E6/E7 as described in Harris et al (2011) . .. Murine anti-HPV16-E6 C1P5 and anti-HPV16-E7 20191 mAbs (both of IgG1 isotype) were obtained from Abcam (Boston, MA, USA) and irrelevant isotype matching control murine mAb MOPC21 was procured from Abnova (Taipei, Taiwan).

    Stable Transfection:

    Article Title: Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein
    Article Snippet: The HPV16+ CasKi cell line was obtained from the American Type Culture Collection (Manassas, VA, USA). .. The HPV16+ 2A3 cell line was produced by stably transfecting the FaDu cell line from the American Type Culture Collection with the LXSN 16E6/E7 as described in Harris et al (2011) . .. Murine anti-HPV16-E6 C1P5 and anti-HPV16-E7 20191 mAbs (both of IgG1 isotype) were obtained from Abcam (Boston, MA, USA) and irrelevant isotype matching control murine mAb MOPC21 was procured from Abnova (Taipei, Taiwan).



    Similar Products

    hpv16 2a3 cell line  (ATCC)
    94
    ATCC hpv16 2a3 cell line
    Lactate dehydrogenase assay of CasKi and <t>2A3</t> cells treated in vitro with various concentrations of cisplatin.
    Hpv16 2a3 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hpv16+2a3+cell+line/2A3/pmc03590678-10-1-16
    Average 94 stars, based on 1 article reviews
    hpv16 2a3 cell line - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Lactate dehydrogenase assay of CasKi and 2A3 cells treated in vitro with various concentrations of cisplatin.

    Journal: British Journal of Cancer

    Article Title: Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein

    doi: 10.1038/bjc.2013.43

    Figure Lengend Snippet: Lactate dehydrogenase assay of CasKi and 2A3 cells treated in vitro with various concentrations of cisplatin.

    Article Snippet: The HPV16+ 2A3 cell line was produced by stably transfecting the FaDu cell line from the American Type Culture Collection with the LXSN 16E6/E7 as described in Harris et al (2011) .

    Techniques: Lactate Dehydrogenase Assay, In Vitro

    Tumour uptake of E6-binding mAb 188 Re-C1P5 in nude mice-bearing CasKi and 2A3 tumours post treatment with cisplatin. Mice were treated with various doses of cisplatin for 3 days, 188 Re-C1P5 mAb was administered 24 h after the last dose of cisplatin, and the tumour uptake was assessed 24 h post 188 Re-C1P5 administration: ( A ) CasKi; ( B ) 2A3; ( C , D ) TUNEL staining of the untreated and cisplatin-treated tumours. Apoptotic cells stained brown. Original magnification × 400: ( C ) CasKi tumours—untreated (left panel) and treated with 5 mg kg −1 cisplatin (right panel); ( D ) 2A3 tumours—untreated (left panel) and treated with 5 mg kg −1 cisplatin (right panel).

    Journal: British Journal of Cancer

    Article Title: Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein

    doi: 10.1038/bjc.2013.43

    Figure Lengend Snippet: Tumour uptake of E6-binding mAb 188 Re-C1P5 in nude mice-bearing CasKi and 2A3 tumours post treatment with cisplatin. Mice were treated with various doses of cisplatin for 3 days, 188 Re-C1P5 mAb was administered 24 h after the last dose of cisplatin, and the tumour uptake was assessed 24 h post 188 Re-C1P5 administration: ( A ) CasKi; ( B ) 2A3; ( C , D ) TUNEL staining of the untreated and cisplatin-treated tumours. Apoptotic cells stained brown. Original magnification × 400: ( C ) CasKi tumours—untreated (left panel) and treated with 5 mg kg −1 cisplatin (right panel); ( D ) 2A3 tumours—untreated (left panel) and treated with 5 mg kg −1 cisplatin (right panel).

    Article Snippet: The HPV16+ 2A3 cell line was produced by stably transfecting the FaDu cell line from the American Type Culture Collection with the LXSN 16E6/E7 as described in Harris et al (2011) .

    Techniques: Binding Assay, TUNEL Assay, Staining

    Therapy with cisplatin and RIT with E6-binding mAb 188 Re-C1P5 of nude mice-bearing 2A3 ( A ) and CasKi ( B ) tumours. T n—tumour volume on the day of measurement; T 0 —tumour volume on day 0. The mice with 2A3 HNSCC tumours were treated IP with: 400 μ Ci 188 Re-C1P5 mAb on day 0; or 5 mg kg −1 per day cisplatin on days 0, 1, 2 followed by 400 μ Ci 188 Re-C1P5 mAb on day 3; or 5 mg kg −1 cisplatin alone on days 0, 1, 2; or left untreated. The mice with CasKi cervical tumours were treated IP with: 200 μ Ci 188 Re-C1P5 mAb on day 0; or 5 mg kg −1 per day cisplatin on days 0, 1, 2 followed by 200 μ Ci 188 Re-C1P5 mAb on day 3; or 5 mg kg −1 cisplatin alone on days 0. 1, 2; or left untreated.

    Journal: British Journal of Cancer

    Article Title: Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein

    doi: 10.1038/bjc.2013.43

    Figure Lengend Snippet: Therapy with cisplatin and RIT with E6-binding mAb 188 Re-C1P5 of nude mice-bearing 2A3 ( A ) and CasKi ( B ) tumours. T n—tumour volume on the day of measurement; T 0 —tumour volume on day 0. The mice with 2A3 HNSCC tumours were treated IP with: 400 μ Ci 188 Re-C1P5 mAb on day 0; or 5 mg kg −1 per day cisplatin on days 0, 1, 2 followed by 400 μ Ci 188 Re-C1P5 mAb on day 3; or 5 mg kg −1 cisplatin alone on days 0, 1, 2; or left untreated. The mice with CasKi cervical tumours were treated IP with: 200 μ Ci 188 Re-C1P5 mAb on day 0; or 5 mg kg −1 per day cisplatin on days 0, 1, 2 followed by 200 μ Ci 188 Re-C1P5 mAb on day 3; or 5 mg kg −1 cisplatin alone on days 0. 1, 2; or left untreated.

    Article Snippet: The HPV16+ 2A3 cell line was produced by stably transfecting the FaDu cell line from the American Type Culture Collection with the LXSN 16E6/E7 as described in Harris et al (2011) .

    Techniques: Binding Assay

    18 F-FDG microPET/CT images of 2A3 tumour-bearing on day 15 post treatment: left panel—untreated mouse, middle panel—the mouse treated with cisplatin alone, right panel—the mouse treated with cisplatin and RIT. Green arrows are pointing to the tumours.

    Journal: British Journal of Cancer

    Article Title: Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein

    doi: 10.1038/bjc.2013.43

    Figure Lengend Snippet: 18 F-FDG microPET/CT images of 2A3 tumour-bearing on day 15 post treatment: left panel—untreated mouse, middle panel—the mouse treated with cisplatin alone, right panel—the mouse treated with cisplatin and RIT. Green arrows are pointing to the tumours.

    Article Snippet: The HPV16+ 2A3 cell line was produced by stably transfecting the FaDu cell line from the American Type Culture Collection with the LXSN 16E6/E7 as described in Harris et al (2011) .

    Techniques:

    Immunohistochemical evaluation of E6 and E7 oncogenes expression in RIT-treated CasKi and 2A3 cells. ( A ) E6 in CasKi cells, ( B ) E7 in CasKi cells; ( C ) E6 in 2A3 cells; ( D ) E7 in 2A3 cells. Left panels show untreated cells and right panels RIT-treated cells. Cells positive for E6 and E7 oncogenes stained brown. Original magnification × 400.

    Journal: British Journal of Cancer

    Article Title: Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein

    doi: 10.1038/bjc.2013.43

    Figure Lengend Snippet: Immunohistochemical evaluation of E6 and E7 oncogenes expression in RIT-treated CasKi and 2A3 cells. ( A ) E6 in CasKi cells, ( B ) E7 in CasKi cells; ( C ) E6 in 2A3 cells; ( D ) E7 in 2A3 cells. Left panels show untreated cells and right panels RIT-treated cells. Cells positive for E6 and E7 oncogenes stained brown. Original magnification × 400.

    Article Snippet: The HPV16+ 2A3 cell line was produced by stably transfecting the FaDu cell line from the American Type Culture Collection with the LXSN 16E6/E7 as described in Harris et al (2011) .

    Techniques: Immunohistochemical staining, Expressing, Staining